Prof Nicolas Girard speaks to ecancer about preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib.

The COCOON trial assesses a proactive dermatologic management strategy to prevent adverse events from amivantamab and lazertinib in lung cancer treatment.

It shows a 50% reduction in severe dermatologic issues compared to standard of care.

The MARIPOSA trial highlights amivantamab and lazertinib's survival benefits, despite increased dermatological risks.

This new approach enhances patient experience with this treatment and is poised for broader clinical adoption.